Presenting Health Incubator Helsinki batch 4 companies:

Finnish biotech startup R2therapies has recently identified a potential biomarker in the blood of Alzheimer’s disease patients, offering insight into the likelihood of developing severe symptoms. In time, the company’s discovery could potentially lead to an approved diagnostic tool. R2therapies is one of the startups selected for the Health Incubator Helsinki 2023 programme.

Alzheimer’s disease is a progressive neurodegenerative disorder, characterised by cognitive decline, memory loss, and behavioural changes. It is the most common cause of dementia, with no existing cure.Moreover, Alzheimer’s is a heterogeneous disease, with varying underlying causes and disease progression. This makes it difficult to predict which pre-Alzheimer’s patients end up with the most severe form of the disease. It is also a challenge for pharmaceutical companies who may miss detecting meaningful treatment responses during clinical trials possibly due to participant heterogeneity.

R2therapies’ biomarker not only predicts the likelihood of Alzheimer’s, but identifies the risk of severe dementia.

Photo from left: Tarja Malm, Rashid Giniatullin, Ilkka FagerlundA biomarker, in turn, is a measurable indicator of a specific biological state or condition, such as elevated body temperature signaling an infection. Biomarkers can also possess predictive capabilities, like high cholesterol levels indicating an elevated risk of heart disease.R2therapies tackles the challenges Alzheimer’s poses with a biomarker that not only predicts the likelihood of Alzheimer’s, but identifies the risk of severe dementia. This capability stems from R2therapies’ team’s biological discoveries.

An unexpected scientific discovery

“It is fair to say that R2therapies is a the results of a chain of coincidences. It all started as a drug development project,” says Ilkka Fagerlund, co-founder of R2therapies.In Kuopio, Finland, a team of scientists studying brain cells encountered unexpected results during a routine experiment. Although initially perceived as a technical problem hindering their research, further investigation revealed the occurrence to be a genuine biological phenomenon and a prospective novel therapeutic target for Alzheimer’s that the team recently published.This phenomenon, identified through extensive review of scientific literature, appears to be a physiological property of red blood cells which has not been linked to Alzheimer’s disease before.“We connected these findings and analysed patient samples from Kuopio University Hospital, and showed that the same mechanism is also affected in the red blood cells of Alzheimer’s patients that revealed a previously unidentified feature related to Alzheimer’s disease – one that we are looking to translate into a biomarker to predict the onset of Alzheimer’s, and possibly to stratify the patients into distinct subsets that may in the future benefit from different treatments,” Fagerlund says.

R2therapies Fast Facts

Name: R2therapies OyTech in one sentence: New biomarker for Alzheimer’s diseaseTarget product: Blood test to identify risk of developing severe Alzheimer’s diseaseMarket launch: 2028Founded: 2022Team size: <10Funding status: Looking to raise the seed investment in 2026

From research-use to clinical reality

Existing biomarkers for Alzheimer’s are related to the symptoms of the disease, and can often be detected once it’s too late. A kit that could diagnose patients before the onset of symptoms means that the patient can start receiving treatment sooner.The R2therapies team is still uncovering the biological reasons behind the presence of their new biomarker. In addition to continuing the validation in early Alzheimer’s patients, they are also exploring the behaviour of the biomarker in other neurodegenerative diseases, such as frontotemporal dementia, Lewy body disease and Parkinson’s disease to understand the biomarker’s differential diagnosis potential.The first step towards clinical use-case will be to develop the biomarker analysis kit for research-use for clinical doctors who also conduct academic research, and with rigorous validation it could potentially be available as an approved diagnostic tool.

First step towards clinical use-case will be to develop the biomarker analysis kit for research-use.

Health Incubator Helsinki supports scientists in business

Incubator programs like Health Incubator Helsinki are a game-changer for researchers who do not typically receive business training.“Health Incubator Helsinki stands out as a comprehensive program from which I have learned a lot,” Fagerlund says.“I remember a particularly good seminar about contracts. I was surprised that there are so many different types such as shareholder agreements, client agreements, and so on.”As the R2therapies team is still starting out and the development is in its initial phase, the company is  looking for investments. To support their goals,  Health Incubator Helsinki has connected the company with investors.The team also expects to gain a lot from the various opportunities, webinars, and events organised by HIH. Moreover, the incubator program advisors have the expertise and experience to transition R2therapies’ innovation into a market-ready kit. This involves leveraging the program’s expertise and network for clinical validation, and navigating regulatory considerations.Interested in getting involved with R2therapies? Please refer to the contact information below.Contact R2therapies: ilkka.fagerlund@uef.fiRead more:Here is the Health Incubator Helsinki batch of 2023
Check out all the companies in the Health Incubator Helsinki programmeText: Rita Turpin, Giuliano Didio
Health Capital Helsinki